Topotecan

Lirbonectin is a one-hour IV infusion given every three weeks suitable for outpatient infusion centers.

And then I think lastly, TopoTecan is available in both oral and IV formulations with the oral TopoTecan offering home-based administration options as relevant as they are.

So, Dr. Sands, how would you monitor this patient's response to subsequent systemic therapy? You talked about the ideal treatment, what's driving that efficacy, but how does monitoring start to evolve to upon this subsequent line of treatment?

So, with tarlatumab as second-line treatment, I would monitor every six weeks initially.

So with a hazard ratio of 0.46, this translates into a 54% reduction in the risk of death for patients in the Tampali arm.

Median progression-free survival was 7.4 months in the Tampali arm compared to 2.8 months in the Topotecan arm.

And with a hazard ratio of 0.29, this translates into a 71% reduction in the risk of disease progression or death in the Tampelli arm.

That's just huge.

The objective response rate was 59.1% in the Tampelli arm compared to 9.7% in the Topotecan arm.

Additionally, disease control rate, which is a big issue for our small cell lung cancer patients, was 91% with Tampelli compared to 50.9% in the topotecan arm.

Now in both arms, about 34% of patients had brain mets.

And what was really great to see was that Tampelli also improved intracranial PFS, ORR, and DCR compared to topotecan.

Yes, there are real case reports of toxicity, and similar drugs like everolimus are often used in cancer treatment.

Other drugs with similar interactions are doxorubicin, the whole Taxol family, the Tecan family, Irinotecan, Topotecan, and some of the tyrosine kinase inhibitors.

And also, the one that nobody really checks, berberine can prolong what we call the QT interval, or the space in between heartbeats, which is a heart rhythm risk.

If you stack berberine on top of cancer drugs that already do that, and many of them do...

Artemis is an open study of the third phase and is designed to evaluate the effectiveness and safety of the conjugate of the antibody and the drug, which targets B7H3, called Rizvutatuk Rezetekan.

In direct comparison with standard chemotherapy, specifically with Topotekan, for patients who have relapsing malignant pulmonary carcinoma and these patients also performed chemotherapy based on platen with immunotherapy or without it.

The primary goal of this study was to ensure the overall survival.

The median of the overall survival for Rizvutatuk Rezetekan was 18.5 months, for Topotekan it was 10.3 months.

And the safety profile of this new material was favorable.

It is without a doubt about a molecule, which is again mispronounced.

For many years we have not had any kind of gain, mainly in terms of survival in patients with metastatic disease.

And today we had the Taishan 302, which was a phase 3 study that compared the ADC before B7H3, the Tambotatug Pelitecan from Medlink, which is a Chinese company, against Topotecan, and then Artemis 008, which was also a phase 3, comparing Risvutatumag, Resetecan, we have to do a class to say these names, which is a DC before B7H3, also from a Chinese company, Ransom Pharma, against Topotecan.

So, Vlad, Tell us a little bit about these studies.

I think, first of all, I'm very happy that in the last three or four years we've seen a very rapid progress in the treatment of small cell cancer.

Tampel has a dose of 8, and His Rest has a dose of 4.

This is important for a discussion that we will have later, which is about the profile of collateral effect that we saw in these two studies.

And both studies compared, it was in the second line, the assessment of these drugs in the second line, comparing with Topotecano, which, as we know, is what we had as a standard for a long time, but a very common drug, both

in terms of